Your assumption is correct. The reporting requirement applies to all companies in Switzerland which after the expiration of the transitional period use a substance listed in Annex 1.17 Number 5 and in regard to the intended use cannot rely on a general exemption in accordance with Annex 1.17 Number 2 paragraph 1.
On the reporting requirement in accordance with Number 3 of Annex 1.17: are we correct in assuming that this reporting requirement is in addition to the authorisation requirement? Or is this reporting requirement intended for the exemptions in accordance with Number 2 Annex 1.17?
Last modification 17.07.2019
